title: Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis.
abstract: To present the results of recurrent respiratory papillomatosis (RRP) treatment with surgical excision and adjuvant anti-viral cidofovir intralesional use and to examine the correlation between the cidofovir effectiveness and the patient previous history of multiple larynx procedures, age, extension of lesion and dose. 32 patients with laryngeal papillomas were treated with cidofovir in our Department between I.2009 and I.2011. The number of previous RRP debulking procedures ranged from 1 to 100. The intensity of papillomatosis differed from one anatomic site and moderate growth to four or five localizations with heavy extension. The number of injections per patient varied from 1 to 7, and the total volume of 5 mg/ml solution varied from 2 to 33 ml. The injections were combined with laser debulking of the lesions. In disperse papillomata, the injections were administered in particular anatomical sites in 4-6 weeks intervals, in massive lesions injections were repeated in the same anatomical site in 2-4 weeks. Complete remission was observed in 18 out of 32 patients. 13 patients showed remission in a place of cidofovir injection. One patient did not react to the drug. In four patients, new changes in injection places appeared. In two patients, hepatic toxic side effects were observed. Intralesional cidofovir injection has been shown to be an effective and safe therapy for laryngeal papillomatosis and should be considered in those patients who experienced disease relapse.
authors.affiliation: Department of Otolaryngology, Poznań University of Medical Sciences, Poznań, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Wierzbicka
authors.forename: Joanna
authors.initials: J
authors.lastname: Jackowska
authors.forename: Anna
authors.initials: A
authors.lastname: Bartochowska
authors.forename: Agata
authors.initials: A
authors.lastname: Józefiak
authors.forename: Witold
authors.initials: W
authors.lastname: Szyfter
authors.forename: Witold
authors.initials: W
authors.lastname: Kędzia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D000077404:Cidofovir; D015331:Cohort Studies; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D053685:Laser Therapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir